



(12) Translation of
European patent specification

(11) NO/EP 2608808 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 39/395 (2006.01)
A61K 38/17 (2006.01)
A61K 38/20 (2006.01)
A61P 35/00 (2006.01)
C07K 16/24 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.05.29
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.01.18
(86)	European Application Nr.	11820492.4
(86)	European Filing Date	2011.08.23
(87)	The European Application's Publication Date	2013.07.03
(30)	Priority	2010.08.23, US, 376097 P 2010.10.26, US, 406759 P 2010.11.08, US, 411183 P 2011.04.29, US, 201161480635 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	XBiotech, Inc, 1055 West Hastings Street, Suite 300, Vancouver, BC V6E 2E9, CA-Canada
(72)	Inventor	SIMARD, John, 8201 East Riverside DriveBldg. 4, Suite 100, Austin, TX 78744, US-USA
(74)	Agent or Attorney	Plougmann Vingtoft, Postboks 1003 Sentrum, 0104 OSLO, Norge

(54)	Title	TREATMENT FOR NEOPLASTIC DISEASES
(56)	References Cited:	WO-A2-2010/030979 WO-A2-2010/087972 US-A- 5 959 085 US-A1- 2006 127 407 US-A1- 2009 298 096 US-A1- 2010 040 574 CHARLES A. DINARELLO ET AL: "Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases", NATURE REVIEWS DRUG DISCOVERY, vol. 11, no. 8, 1 August 2012 (2012-08-01) , pages 633-652, XP055051238, ISSN: 1474-1776, DOI: 10.1038/nrd3800 ZHONG CHEN ET AL.: 'Effects of interleukin-1a, interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines' CANCER RESEARCH vol. 58, no. 16, 1998, pages 3668 - 3676, XP055084716

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 5 **1.** Et anti-IL-1 α -antistoff for anvendelse ved behandling av en neoplastisk sykdom i et menneske; hvor den neoplastiske sykdommen er valgt fra Burkitts lymfom, nasofaryngeal kreft eller Castlemans sykdom.
- 10 **2.** Anti-IL1 α -antistoff for anvendelse ifølge krav 1, hvor anti-IL-1 α -antistoffet er et monoklonalt antistoff.
- 15 **3.** Anti-IL1 α -antistoff for anvendelse ifølge krav 2, hvor det monoklonale antistoffet er en IgG1.
- 4.** Anti-IL1 α -antistoff for anvendelse ifølge krav 1, hvor den neoplastiske sykdommen er nasofaryngeal kreft.
- 5.** Anti-IL1 α -antistoff for anvendelse ifølge krav 1, hvor den neoplastiske sykdommen er Castlemans sykdom.
- 20 **6.** Anti-IL1 α -antistoff for anvendelse til å redusere størrelsen av en tumor i et menneske.